Skip to main contentSkip to navigationSkip to search


Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine

December 21, 2020
 | Regulatory
As previously communicated in connection with the IPO the results from the phase II study performed by researchers at Rigshospitalet were available in 2020. Following data analysis, a scientific manuscript covering the results has been submitted by the research group to the Journal of Nuclear Medicine where it underwent a stringent peer-review process. Following this process, the manuscript has been accepted for publication in an upcoming issue of the Journal of Nuclear Medicine probably during H1 2021.

Japanese patent application 2019-005811 is accepted for grant

December 16, 2020
 | Regulatory
The Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.

Financial Calendar 2021

December 15, 2020
 | Regulatory
Curasight A/S (Ticker: CURAS, CURAS T01) today announces that the company expects to publish financial reports according to the following schedule:

Interim report January – September 2020

November 30, 2020
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2020. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement

November 11, 2020
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) today announces that it has initiated the pre-clinical study of uPAR targeted radionuclide therapy (uTREAT[®]) in brain cancer and signed an agreement with the Danish CRO Minerva Imaging A/S (“Minerva Imaging”), to conduct the pre-clinical study. The initiation of the pre-clinical study is thus in line with previously communicated targets. Minerva Imaging has provided Curasight with a cost-efficient proposal that ensures that the Company’s communicated timelines are kept. Results are, as earlier communicated, expected to be available during 2021.

Canadian patent application relating to uTRACE[®] is ready for allowance in Canada

October 22, 2020
 | Regulatory
The Canadian Intellectual Property Office has announced that Curasight’s Canadian patent application CA 2,903,261 is ready for allowance and the patent will be issued. This patent application relates to Curasight’s imaging technology relating to uTRACE[®] (imaging agent [68]Ga-NOTA-AE105) and uses thereof until 2034.

First day of trading in Curasight’s shares and warrants at Spotlight Stock Market

October 8, 2020
 | Regulatory
Today is the first day of trading in Curasight A/S ("Curasight") shares and warrants of series TO 1. Curasight’s shares are traded under the ticker "CURAS" with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker "CURAS TO 1" with ISIN DK0061408747.

Prolongation and expansion of agreement with TRT Innovations ApS

October 7, 2020
 | Regulatory
Today, the 7 October, 2020, Curasight A/S (“Curasight” or the “Company”) has entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.

Significantly oversubscribed IPO of units in Curasight

September 22, 2020
 | Regulatory
The subscription period for Curasight A/S ("Curasight") IPO of units (shares and consideration free warrants) ended on September 17[th] 2020. The initial part of the IPO of units was subscribed to a total of approx. DKK 273 million, corresponding to a subscription ratio of approx. 835 percent, and Curasight will thereby be provided approx. DKK 32.7 million (before issue costs) through the IPO of units. Through the issue of units, Curasight receives approx. 1,700 new shareholders. In addition to the IPO of units, the company has executed a directed issue of units to the same terms as the IPO, which will provide Curasight with an additional approx. DKK 14 million (before issue costs). Settlement notes are scheduled to be sent out today, September 22[nd], 2020. Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in connection with the capitalization and listing.

Webcast with Curasight

September 9, 2020
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented the company, its operations and future plans, via a webcast together with Biostock. See below for more information.
Load more